Aces is a healthcare technology company that provides an end-to-end electronic data capture (EDC) platform for use in clinical trials, ranging from pharmaceutical trials to medical device trials. Our EDC software is a BYOD (bring your own device) mobile and web based software as a service (SaaS) that captures and tracks an enormous amount of patient data electronically as well as the communications between the patient and the clinical trial organizer. This data is essential to clinical safety and efficacy protocols, enabling previously impossible real-time insights in the clinical research phase of drug and device development and reducing overall costs of a clinical trial. For the first time in clinical trials, our patent pending software supports over 15k integrations, including 200+ FDA-approved Bluetooth medical devices and wearable health trackers.
The collection of valuable lifestyle data provided by these Bluetooth enabled devices is currently not done in clinical trials. The Aces software not only captures a larger amount of more robust data, but also provides a comprehensive overview of current trial progress, successes, warning signs, and patient status at the patient, site, trial, and CRO levels. These analytics provide insights into which trial sites had the highest enrollment, the best protocol adherence, and more. This level of data capture and analytics is what differentiates Aces and provides our customers with competitive advantages.
Aces ensures that documentation is generated, archived, and submitted in addition to utilizing automated reminders to patients/staff via our intuitive, easy to use patient facing mobile application to improve patient adherence through the use of. These features reduce the massive delays and costs of obtaining FDA approval for a new drug or medical device and help researchers find breakthroughs sooner. Aces is the only solution that can aggregate data from any source in real time, and is 100% customizable by the sponsor.
Aces is currently playing an integral role in a groundbreaking study for a novel autism treatment. This phase II clinical trial is based on some of the most publicized research in ASD (Autism Spectrum Disorder) over the last year, the results of which are among the most anticipated in medicine. Specifically, these outcomes will shape the future of innovation surrounding the microbiome and its manipulation in central nervous system disorders, including autism, one of the toughest enigmas to crack in modern health.
Due to data regulatory concerns about potential fever complications in trial subjects, the Phase II study was originally slated to go on a full clinical hold by the FDA. However, Aces technology in partnership with a bluetooth thermometer, was able to remove the hold and ease the FDA’s concerns. Through triaging of temperature readings and data integration in the Aces platform, this trial can now continue through real-time adverse event reporting, ensuring fever-related complications are being triaged in real time, minimizing risk associated with the new type of treatment.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.